Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for Upfront $850 Million
By Ian Walker
Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment of $850 million.
The U.S. clinical-stage biotechnology company said Monday that Genentech will pay further sums based on certain pre-determined development, regulatory and commercial milestones being met.
As part of the deal Genentech will be responsible for clinical development, manufacturing and worldwide commercialization of the inhibitors, while Regor will continue to manage two current Phase 1 trials.
Regor will also advance its other distinct assets, unrelated to this deal, in oncology, metabolic diseases and auto-immunity, the company said.
The deal is expected to close in the fourth quarter of this year, subject to the usual conditions.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
September 30, 2024 01:44 ET (05:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks